FDA Reports About Singulair Medication
The US Food and Drug Administration (FDA) investigates a prescription drug Singulair (Montelukast) used in treating asthma and allergic rhinitis. It intends to reveal a potential link between the drug’s use and changes to behavior and mood, suicide, and suicidal thinking and behavior if it takes place. According to the announcement made on 27th of March in an Early Communication About an Ongoing Safety Review it does not mean that the drug causes symptoms of sneezing, runny, itchy and stuffy nose and neither does it mean to stop prescribing asthma meds.
Due to adverse events reported during the post-marketing phase, Merck & Co alerted doctors and patients to the following side effects of Montelukast tablets: tremor, depression, suicidal thinking and behaviour, and anxiousness.
in the last 12 months, , have updated the patient and prescribing information for Singulair three times to, said the FDA.
But as The FDA says it is not an ultimate conclusion. It needs further analyses and more information. The drug company intends to tell doctors about the changes so they can inform their patients about the risks of taking Singulair medication.
More, doctors and healthcare professionals should monitor all patients receiving Montelukast 10 mg for signs of suicidal thinking and behaviour, and other changes in mood and behaviour.
Therefore, The FDA marked that generic Singulair is an effective medication for the treatment of asthma and symptoms of allergic rhinitis and patients should not stop Singulair drug therapy without consulting their doctor.
By the way, Singulair tablets are currently confirmed in the US for adults and children 12 months and over for the relief of symptoms of allergies.
And you can buy Singulair drug online.
In addition, the agency is thinking over similar potential side effects in other leukotriene receptor antagonists, Accolate, Zyflo, and Zyflo CR. These allergy relief products might be investigated further.
